Treatment-related mortality (TRM) is a major obstacle to successful allogeneic hematopoietic stem cell transplantation (HSCT). A variety of drugs are used in allogeneic HSCT, and a genetic polymorphism in metabolic enzymes could affect the metabolism of drugs and potentially influence TRM. Here, we focused attention on GSTM1 and GSTT1 enzymes, which metabolize chemotherapeutic agents, chemical carcinogens and by-products of oxidative stress and are absent from more than 50% of some populations. To assess the significance of homozygous GSTM1 and GSTT1 gene deletion in HSCT, we analyzed DNA from 373 patients with hematological disease and their HLA-identical unrelated bone marrow donors using PCR. Homozygous GSTM1 and GSTT1 gene deletions were observed in 56 and 45% of patients, respectively, and 57 and 46% of donors, respectively. There was no significant association between GSTT1 polymorphism and any outcome. However, a GSTM1-positive genotype in recipients was significantly associated with higher TRM and lower survival. These results suggest that a GSTM1-null genotype in recipients protects against TRM after allogeneic HSCT. Further studies are needed to elucidate a mechanism of increased risk for TRM in GSTM1-positive recipients.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for hematological diseases but also carries a risk of treatment-related mortality (TRM) resulting from chemoradiotherapy, graft-versus-host disease (GVHD) or its treatment, and infections. 1 A variety of drugs are used in allogeneic HSCT, such as chemotherapeutic agents, immunosuppressants, antibiotics, antifungal and antiviral drugs; thus, a genetic polymorphism in metabolic enzymes could affect the metabolism of drugs and influence subsequent TRM after HSCT.
We recently reported a metabolic enzyme, UDP glycosyltransferase 2 family, polypeptide B17 (UGT2B17), has a null phenotype at frequencies of 11 and 85% among Caucasians and Japanese populations, respectively, 2 and identified the use of a UGT2B17-positive donor as an independent risk factor for higher TRM and lower survival after HSCT. 3 Here, we focused attention on glutathione Stransferase (GST) M1 and GSTT1 enzymes. These enzymes mainly metabolize chemotherapeutic agents, chemical carcinogens and by-products of oxidative stress, 4 and are absent from more than 50% of some populations. [5] [6] [7] We analyzed the association between homozygous GSTM1 and GSTT1 gene deletions in the donor or recipient with various outcomes of transplantation and found GSTM1-positive recipients were significantly associated with higher TRM and lower survival. These results suggest that some reactive intermediates or toxic metabolites generated by GSTM1 may initiate or promote the development of TRM.
Patients and methods

Patients
The study population was selected from the patients who received bone marrow transplantation from an unrelated donor through the Japanese Marrow Donor Program (JMDP) between January 1993 and March 2000. The selection criteria for the patients and donors in the study population were (1) donor/recipient pairs matched for all genotypes of HLA-A, -B, -C and DRB1, (2) an intensive myeloablative pretransplant conditioning regimen, (3) an unmanipulated marrow graft, (4) the use of cyclosporin A (CsA) or tacrolimus as GVHD prophylaxis, (5) DNA samples were stored and available for genotyping, and (6) clinical outcome data were available. The genotypes of each allele at the HLA-A, -B, -C and DRB1 loci were determined by high-resolution DNA typing as described previously. 8, 9 The characteristics of the 373 patients are summarized in Table 1 . Standard-risk disease was defined as acute myeloid leukemia or acute lymphoblastic leukemia in first remission, chronic myeloid leukemia in first chronic phase or myelodysplastic syndrome classified as refractory anemia. All other hematological malignancies including Hodgkin's lymphoma and non-Hodgkin's lymphoma were considered advanced disease. The pretransplant conditioning regimen varied according to disease or stage of disease at transplantation. GVHD prophylaxis consisted of either CsA plus short-term methotrexate (sMTX)7anti-thymocyte globulin, or tacrolimus plus sMTX.
TRM was defined as any death that occurred while the patient was in remission. The assessment and grading of acute and chronic GVHD were performed as described previously. 10, 11 A final clinical survey of these patients was carried out on July 1, 2001 , and the median follow-up period was 45 months (range, 0-111 months). Stored DNA was available from all 373 recipients and from 313 donors for analysis of GSTM1 and GSTT1 genotype. Informed consent was obtained from all patients and donors, and approval was obtained from the ethics committee at Nagoya University School of Medicine.
Determination of homozygous deletion of the GSTM1 and GSTT1 genes The homozygous deletion of the GSTM1 and GSTT1 genes was determined by PCR on genomic DNA from donor and recipient cells. The sense and antisense primers used for PCR to detect the GSTM1 gene were 5 0 -GAACTC CCTGAAAAGCTAAAGC-3 
Statistical analysis
A w 2 test with 2 Â 2 contingency tables was used to evaluate differences of the frequencies of homozygous GSTM1 and GSTT1 genes deletion between patients and donors. The Cox proportional-hazard model was applied to multivariate analysis for TRM, acute and chronic GVHD, relapse, disease-free survival (DFS) and overall survival (OS). 12 The following variables were evaluated in a univariate analysis: patient age (continuous variable); disease status of hematological malignancy at the time of transplantation (advanced disease versus standard disease); GVHD prophylaxis (CsA containing regimen versus tacrolimus containing regimen); pretransplant conditioning regimen (TBI containing versus non-TBI containing); incidence of acute GVHD (only for analysis about chronic GVHD) (grade II-IV versus grade 0-I and grade III-IV versus grade 0-II); patient GSTM1 and GSTT1 genotype (deleted versus positive); and donor GSTM1 or GSTT1 genotype (deleted versus positive). All variables with Po0.10 were entered into the multivariate logistic regression using a backward, stepwise method. Po0.05 was regarded as statistically significant, and those between 0.05 and 0.1 as suggestive of a trend. The TRM, DFS and OS were estimated by using the Kaplan-Meier method, and log-rank test was used to analyze differences. 
TRM
Of 367 evaluable patients for TRM, 115 (31.3%) were dead without relapse at the time of survey. In a univariate analysis, higher patient age, advanced disease and GSTM1-positive patient were associated with higher TRM (Table 2 ). There was no significant association between GSTT1 genotype in either patient or donor and TRM. In a multivariate analysis, GSTM1-positive patient as well as higher patient age and advanced disease were significantly associated with higher TRM. TRM was analyzed in relation to GSTM1 genotype in the patient by the Kaplan-Meier method (Figure 1a) . TRM in the GSTM1-positive patients was significantly higher than that in the GSTM1-negative patients (42.9 versus 29.3%; P ¼ 0.04).
Because death after day 200 may include treatment-'unrelated' death, we analyzed TRM within 200 days after transplant in relation to GSTM1 genotype in the patient (Figure 1b) . TRM within 200 days in the GSTM1-positive patients was also significantly higher than that in the GSTM1-negative patients (28.8 versus 18.7%; P ¼ 0.04). Forty-four of GSTM1-positive patients died within 200 days after transplant while they were in remission. Causes of death in the patients were rejection/graft failure (n ¼ 3; 6.8%), GVHD (n ¼ 11; 25.0%), interstitial pneumonia (n ¼ 8; 18.2%), sepsis (n ¼ 7; 15.9%), bleeding (n ¼ 3; 6.8%), veno-occlusive disease (VOD) (n ¼ 2; 4.5%), adenovirus infection (n ¼ 1; 2.3%), myocardiopathy (n ¼ 1; 2.3%), cerebral infarction (n ¼ 1; 2.3%), hemolytic uremic syndrome (n ¼ 1; 2.3%), leukoencephalitis (n ¼ 1; 2.3%), pneumonia (n ¼ 1; 2.3%) and unknown (n ¼ 4; 9.6%). Thirty-seven of GSTM1-negative patients died within 200 days after transplant while they were in remission. Causes of death in the patients were rejection/graft failure (n ¼ 1; 2.7%), GVHD (n ¼ 7; 18.9%), interstitial pneumonia (n ¼ 13; 35.1%), sepsis (n ¼ 6; 16.2%), bleeding (n ¼ 3; 8.1%), VOD (n ¼ 1; 2.7%), heart failure (n ¼ 2; 5.4%), renal failure (n ¼ 1; 2.7%), hemosiderosis (n ¼ 1; 2.7%), thrombotic microangiopathy (n ¼ 1; 2.7%) and unknown (n ¼ 1; 2.7%). There was no significant difference in the frequencies of each cause of death between two patient groups (P ¼ 0.52). 
Impact of GSTM1 genotype to BMT outcome S Terakura et al
It is suggested that a polymorphism of GSTM1 may be associated with risk of VOD development, especially if the patients received busulfan (BU) and/or cyclophosphamide (CY) as a pretransplant conditioning regimen. 14, 15 We therefore analyzed the association between GSTM1 polymorphism and death from VOD in the subgroups of patients. In the patients who received BU ( þ others) (n ¼ 105), none of the GSTM1-positive patients (n ¼ 47) died of VOD, whereas one of the GSTM1-negative patients (n ¼ 58) died of VOD (not significant). In the patients who received CY ( þ others) (n ¼ 333), two of the GSTM1-positive patients (n ¼ 145) died of VOD, whereas none of the GSTM1-negative patients (n ¼ 188) died of VOD (not significant).
GVHD
Of 370 evaluable patients, 132 (35.7%) developed grade II-IV acute GVHD. No significant association was detected between the GSTM1 or GSTT1 deletion in the patient or donor with the incidence of grade II-IV acute GVHD (Table 2) . Forty-one (11.1%) patients developed grade III-IV acute GVHD, but no factor was detected as a risk factor for a higher incidence of grade III-IV acute GVHD.
Of 304 evaluable patients, 124 (40.8%) developed chronic GVHD, including 48 (15.8%) with a limited type and 76 (25.0%) with an extensive type. No significant association was detected between the GSTM1 or GSTT1 deletion in the patient or donor with the incidence of chronic GVHD (Table 2 ).
Relapse
Of 348 evaluable patients with a malignant disease, 74 (21.3%) relapsed after transplantation. No significant association was detected between the GSTM1 or GSTT1 deletion in the patient or donor with a relapse rate ( Table 2) .
DFS and OS
Of 348 evaluable patients with a malignant disease, 177 (50.9%) were alive at the time of survey, including 165 (47.4%) patients who were alive without relapse. In a univariate analysis, higher patient age, advanced disease and GSTM1-positive patient were significantly associated with lower DFS and OS (Table 2 ). GSTT1 genotype in either patient or donor was not associated with DFS and OS. In a multivariate analysis, GSTM1-positive patient as well as higher patient age and advanced disease were significantly associated with lower DFS and OS. DFS and OS were analyzed in relation to GSTM1 genotype in the patient by the Kaplan-Meier method (Figure 2 ). Both DFS and OS in the GSTM1-positive patients were lower than those in the GSTM1-negative patients (DFS, 38.3 versus 54.0%, P ¼ 0.02; OS, 41.1 versus 55.1%, P ¼ 0.07).
Discussion
To evaluate a potential contribution of GSTM1 and GSTT1 genotype to allogeneic HSCT outcome, we determined the frequencies of homozygous deletion of GSTM1 and GSTT1 genes in the patients with a hematological disease and healthy marrow donors. A homozygous deletion of the GSTM1 and GSTT1 genes was found in B57 and B46% of healthy donors, respectively, which was comparable to the previous Japanese studies. 7, 16 Of patients with a hematological malignancy, homozygous deletion of the GSTM1 and GSTT1 genes was found in B56 and B45%, respectively, and there was no difference in the frequencies between each disease group and donor group. The findings, of no association between both GSTM1-and GSTT1-null genotypes and risk of each hematological malignancy, were consistent with our previous study in a different Japanese population; 7 however, many studies have emphasized the importance of these genetic polymorphisms in susceptibility to hematological diseases. 17, 18 The analysis in a larger study size may reveal the role of GSTM1-and GSTT1-null genotypes in the development of hematological malignancies in Japanese people.
The present study demonstrated that a GSTM1-positive patient was significantly associated with higher TRM. GSTs are classified into phase II-metabolizing enzyme group. After phase I, enzymes, in which the cytochrome P450 has a central role, convert xenobiotics into a variety of reactive hydrophobic and electrophilic intermediates, phase II enzymes generally detoxify them by neutralizing reactive electrophiles. 4 GSTs catalyze the nucleophilic addition of thiol of glutathione (GSH) to electrophilic acceptors of various substrates. However, in a minority of the reactions, GSTM1 can activate certain molecules instead of detoxification. GSH conjugates originated from such substrates are relatively unstable and the reaction product requires further detoxification, or is reversely converted into the original compound. Thus, it is possible some reactive intermediates or toxic metabolites can be generated by GSTM1 and initiate or promote the development of TRM.
Although the majority of GST substrates are either xenobiotics or by-products of oxidative stress, GSTs also contribute to the metabolism of endogenous compounds including leukotriene (LT) A4, prostaglandin (PG) D2, PGH2 and PGJ2, as part of their normal biosynthetic pathways.
4 LTB4 and PGI2 were described as markers for the inflammatory processes during GVHD development, 19 suggesting that the absence of GSTM1 may protect the recipient against the production of some inflammatory mediators.
Recently, GSTM1 deficiency in the patients with bthalassemia major was found to be a risk factor for VOD after bone marrow transplantation using BU plus CY as a pretransplant conditioning regimen.
14 BU is metabolized by GSTs including GSTA1, GSTM1 and GSTP1 to form a positively charged sulfonium ion that is toxic to sinusoidal endothelial cells and hepatocytes. CY is metabolized to 4-hydroxycyclophosphamide (HCY) by cytochrome P450, and subsequently to iminocyclophosphamide. Iminocyclophosphamide is conjugated with GSTs and its metabolite is excreted into the bile. As a competing pathway for this detoxification pathway for HCY, the ring-opened form of HCY, aldophosphamide, enters cells and decomposes to phosphoramide mustard, the final cytotoxic metabolite, and acrolein through b-elimination. 15 Thus, BU metabolites and/or CY metabolites may increase risk of VOD. We analyzed the association between GSTM1 polymorphism and death from VOD in the subgroup of patients who received BU ( þ others) or CY ( þ others); however, we could not find the effect of GSTM1 polymorphism on fatal VOD. Further studies are clearly needed to determine whether GSTM1 polymorphism is associated with VOD development.
In summary, we assessed the significance of homozygous GSTM1 and GSTT1 gene deletions in the donor or recipient with the outcome of unrelated donor bone marrow transplantation. GSTT1 deficiency was not significantly associated with any outcome. However, the GSTM1-positive recipient was an independent risk factor for higher TRM and lower DFS and OS. It is possible that the presence of the GSTM1-null genotype in recipient may provide better protection against TRM after allogeneic HSCT. Further studies are needed to elucidate a mechanism of increased risk for TRM in GSTM1-positive recipients.
